- Home
- HTH vs BEAM Comparison
HTH vs BEAM Comparison
Compare HTH & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | BEAM |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2003 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HTH | BEAM |
|---|---|---|
| Price | $38.49 | $29.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $37.50 | ★ $50.75 |
| AVG Volume (30 Days) | 197.6K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | 51.72 | ★ 82.31 |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $152,188,000.00 | $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.22 | $33.77 |
| P/E Ratio | $30.37 | ★ N/A |
| Revenue Growth | 15.52 | ★ 33.33 |
| 52 Week Low | $30.78 | $16.03 |
| 52 Week High | $40.41 | $38.26 |
Technical Indicators
Market Signals| Indicator | HTH | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 53.83 |
| Support Level | $38.34 | $28.40 |
| Resistance Level | $40.03 | $34.20 |
| Average True Range (ATR) | 0.57 | 1.36 |
| MACD | -0.09 | 0.46 |
| Stochastic Oscillator | 28.04 | 66.66 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.